JPRN-UMIN000041113
Completed
未知
A study evaluating effectiveness, safety, and pharmacokinetics of the Bictegravir/Emtricitabine/Tenofovir alafenamide single-tablet regimen in treatment-experienced elderly Japanese subjects living with HIV - A study of the Biktarvy targeting elderly Japanese subjects living with HIV.
ational Center for Global Health and Medicine0 sites10 target enrollmentJuly 17, 2020
ConditionsHIV-1 infection
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- HIV-1 infection
- Sponsor
- ational Center for Global Health and Medicine
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Liver cirrhosis (2\)Concurrent medication which might interact with BIC, such as metformin (3\)Patients whose physicians consider the study enrollment inappropriate.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A multi-nutrient intervention for pregnant women experiencing symptoms of depression and anxiety.DepressionAnxietyMental Health - DepressionReproductive Health and Childbirth - Normal pregnancyMental Health - AnxietyACTRN12617000354381Professor Julia Rucklidge88
Active, not recruiting
Phase 1
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)DermatomyositisMedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-003171-35-DECSL Behring LLC126
Active, not recruiting
Phase 1
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)DermatomyositisMedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-003171-35-HUCSL Behring LLC126
Active, not recruiting
Phase 1
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)DermatomyositisMedDRA version: 20.0Level: LLTClassification code 10001403Term: Adult dermatomyositisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-003171-35-ITCSL BEHRING GMBH126
Completed
Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - The RECLAIIM StudyNL-OMON55228CSL Behring LLC